Optional antiviral agents for the COVID-19
10.3760/cma.j.cn115673-20200212-00028
- VernacularTitle:可能用于新型冠状病毒肺炎治疗的抗病毒药物
- Author:
Tingting XIAO
1
;
Kai YANG
;
Chen HUANG
;
Yunying ZHU
;
Zhenzhu WU
;
Yonghong XIAO
Author Information
1. 浙江大学医学院附属第一医院传染病诊治国家重点实验室、国家感染性疾病临床医学研究中心、感染性疾病诊治协同创新中心，杭州 310003
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(2):E012-E012
- CountryChina
- Language:Chinese
-
Abstract:
In December 2019, COVID-19 broke out in Wuhan, China. The disease is highly contagious and quickly spreads at home and abroad, causing great concern. However, there are no definite effective antiviral drugs in clinic. Given the urgency of the COVID-19 outbreak, based on the diagnosis and treatment recommendation and previous researches, this review describes the optional antiviral drugs such as remdesivir, oseltamivir, Arbidol, lopinavir/ritonavir, ribavirin, and interferon-α to provide a reference for the infection therapy.
